These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31306812)

  • 21. Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    Alcacer C; Santini E; Valjent E; Gaven F; Girault JA; Hervé D
    J Neurosci; 2012 Apr; 32(17):5900-10. PubMed ID: 22539851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treadmill Exercise Attenuates L-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice.
    Speck AE; Schamne MG; S Aguiar A; Cunha RA; Prediger RD
    Mol Neurobiol; 2019 Apr; 56(4):2944-2951. PubMed ID: 30073506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
    Ryu YK; Park HY; Go J; Choi DH; Kim YH; Hwang JH; Noh JR; Lee TG; Lee CH; Kim KS
    Mol Neurobiol; 2018 Jul; 55(7):5715-5726. PubMed ID: 29039022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
    Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J
    Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
    Wang Y; Wang HS; Wang T; Huang C; Liu J
    J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals.
    Chotibut T; Fields V; Salvatore MF
    Mol Pharmacol; 2014 Dec; 86(6):675-85. PubMed ID: 25208966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
    Solís O; Espadas I; Del-Bel EA; Moratalla R
    Neurobiol Dis; 2015 Jan; 73():49-59. PubMed ID: 25281315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.
    Han C; Nie S; Chen G; Ma K; Xiong N; Zhang Z; Xu Y; Wang T; Papa SM; Cao X
    Neuroscience; 2017 Jan; 340():23-33. PubMed ID: 27771532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
    Chen YH; Kuo TT; Wang V; Cheng PW; Huang EY; Ma KH; Greig NH; Olson L; Hoffer BJ; Tseng KY
    J Parkinsons Dis; 2024; 14(5):941-964. PubMed ID: 38905058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
    Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
    J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.
    Fanni S; Scheggi S; Rossi F; Tronci E; Traccis F; Stancampiano R; De Montis MG; Devoto P; Gambarana C; Bortolato M; Frau R; Carta M
    Neurobiol Dis; 2019 Jan; 121():120-130. PubMed ID: 30261284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Zhang K; Chammas C; Soghomonian JJ
    Neuroscience; 2015 Sep; 303():586-94. PubMed ID: 26188284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Aguiar AS; Moreira EL; Hoeller AA; Oliveira PA; Córdova FM; Glaser V; Walz R; Cunha RA; Leal RB; Latini A; Prediger RD
    Neuroscience; 2013 Jul; 243():46-53. PubMed ID: 23558088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of striatal ΔFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates.
    Beck G; Singh A; Zhang J; Potts LF; Woo JM; Park ES; Mochizuki H; Mouradian MM; Papa SM
    Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18664-18672. PubMed ID: 31455727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
    Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia.
    Bastide MF; Glangetas C; Doudnikoff E; Li Q; Bourdenx M; Fernagut PO; Dumont ÉC; Georges F; Bézard E
    Sci Rep; 2017 May; 7(1):2348. PubMed ID: 28539659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.